Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size…
- Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- FELINEIndependent statistical analysis of the FELINE phase 2 trial evaluating letrozole plus ribociclib versus letrozole alone as neoadjuvant therapy in ER-positive, HER2-negative early breast cancer.
- FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03212170).
- Fibrin Melanoma Axillary Node Study in Patients With Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Fibrin Melanoma Axillary Node Study in Patients With Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00504582).
- FIGHT-302Independent statistical analysis of FIGHT-302, a randomized phase 3 trial of pemigatinib versus gemcitabine plus cisplatin in unresectable or metastatic cholangiocarcinoma, including progression-free survival, response, overall survival, statistical methodology, safety, and interpretation.
- FIRE-3An independent statistical analysis of the FIRE-3 phase 3 randomized trial comparing FOLFIRI plus cetuximab with FOLFIRI plus bevacizumab in first-line colorectal cancer.
- FIRE-4.5Independent statistical analysis of FIRE-4.5, a randomized phase 2 trial evaluating FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as first-line treatment in BRAF-mutated metastatic colorectal cancer.
- FIRE-6Independent statistical analysis of FIRE-6, a phase 2 clinical trial evaluating FOLFIRI plus cetuximab with avelumab maintenance in RAS wild-type colorectal cancer. Includes trial design, endpoint methodology, planned analysis, and statistical interpretation.
- First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: Complete Statistical AnalysisIndependent statistical analysis of First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone: primary endpoint results, effect estimate with confidence interval,…
- First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Complete Statistical AnalysisIndependent statistical analysis of First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High…
- First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01524991).
- First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): Complete Statistical AnalysisIndependent statistical analysis of FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides): primary endpoint results, effect estimate with confidence…
- Flatbush FHC Proactive Colorectal Cancer Screening and Navigation: Complete Statistical AnalysisIndependent statistical analysis of Flatbush FHC Proactive Colorectal Cancer Screening and Navigation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05646355).
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FLIPPERIndependent statistical analysis of the FLIPPER phase 2 trial of fulvestrant plus palbociclib versus fulvestrant plus placebo as first-line treatment for postmenopausal patients with hormone receptor-positive advanced breast cancer.
- FLOT4An independent statistical analysis of FLOT4 (NCT01216644), evaluating FLOT versus ECF in patients with locally advanced, resectable gastric cancer. Includes trial design, endpoints, statistical methodology, and interpretation.
- FLUBUTBIIndependent statistical analysis of Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366612).
- Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma: Complete Statistical AnalysisIndependent statistical analysis of Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Fluorescent Evaluation of Colorectal Anastamoses: Complete Statistical AnalysisIndependent statistical analysis of Fluorescent Evaluation of Colorectal Anastamoses: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01424293).
- Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases: Complete Statistical AnalysisIndependent statistical analysis of Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases: primary endpoint results, effect estimate with confidence…
- Focal Prostate Radio-Frequency Ablation: Complete Statistical AnalysisIndependent statistical analysis of Focal Prostate Radio-Frequency Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02328807).
- FOCUSIndependent statistical analysis of A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01688336).
- FOLFOXIRIIndependent statistical analysis of the phase 2 FOLFOXIRI trial evaluating FOLFOXIRI plus panitumumab in patients with metastatic KRAS wild-type colorectal cancer with liver metastases only, including trial design, the registered overall response…
- Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- FORESTIndependent statistical analysis of Family History and Cancer Risk Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05079334).
- ForTeIndependent statistical analysis of Building Resiliency Among Caregivers of Curvivors and Metavivors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05702723).
- FORTRESSIndependent statistical analysis of Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- FRESCOAn independent statistical analysis of the phase 3 FRESCO trial of fruquintinib versus placebo in patients with colorectal cancer. Includes trial design, the registered overall-survival endpoint, statistical methodology, planned analysis, and interpretation.
- FRESCO-2Independent statistical analysis of the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care versus placebo plus best supportive care in metastatic colorectal cancer, including overall survival, progression-free survival, response, statistical…
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: Complete Statistical AnalysisIndependent statistical analysis of Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole: Complete Statistical AnalysisIndependent statistical analysis of Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00543127).
- Functional MRI Use in Prostate Radiation Treatment Planning: Complete Statistical AnalysisIndependent statistical analysis of Functional MRI Use in Prostate Radiation Treatment Planning: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01985932).
- Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): Complete Statistical AnalysisIndependent statistical analysis of Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- G-MINORIndependent statistical analysis of Genomics in Michigan Impacting Observation or Radiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02783950).
- Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): Complete Statistical AnalysisIndependent statistical analysis of Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138124).
- Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00880191).
- GALAHADIndependent statistical analysis of the GALAHAD phase 2 study of niraparib in men with metastatic castration-resistant prostate cancer and DNA-repair anomalies, including its single-group design, binary objective response endpoint, RECIST 1.1 and…
- GALAXYComplete statistical analysis of the GALAXY phase 1/2 clinical trial evaluating targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer, including design, endpoints, statistical methodology, planned analyses, and interpretation.
- Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03803475).
- Gardasil Vaccination in Post Stem Cell Transplant Patients: Complete Statistical AnalysisIndependent statistical analysis of Gardasil Vaccination in Post Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01092195).
- GDX-44-016Independent statistical analysis of Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06057168).
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00388154).